scholarly journals Serum-albumin and risk of thyroid cancer: A population-based, matched case-control study,

2009 ◽  
Vol 11 (2) ◽  
Author(s):  
Eystein Glattre ◽  
A. Engeland ◽  
A. T. Høstmark ◽  
E. Jellum
Keyword(s):  
Thyroid Cancer ◽  
Serum Albumin ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Font Size ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

<strong><span style="font-family: TimesNewRomanPS-BoldMT;"><font face="TimesNewRomanPS-BoldMT"><p align="left"> </p></font></span><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">NORSK SAMMENDRAG</span></span></p></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">Flere epidemiologiske undersøkelser fra 1980- og 1990-årene har funnet en invers assosiasjon mellom salbuminnivået</p><p align="left">og sykelighet/dødelighet av kreft. I utforskningen av skjoldkjertelkreftens etiologi og patogenese</p><p align="left">ble det derfor ansett som viktig å finne og bestemme styrken av en slik sammenheng når det gjelder</p><p align="left">skjoldkjertelkreft. Derfor ble alle med tilstrekkelig mengde serum deponert i Janusbanken og som senere i</p><p align="left">perioden 1973-1994, ifølge Kreftregisterets database, hadde fått skjoldkjertelkreft, identifisert – i alt 118</p><p align="left">tilfeller. For hvert tilfelle ble det tilfeldig valgt ut tre friske kontroller med serum i Janus. Kontrollene ble</p><p align="left">matchet mot pasientene hva gjelder kjønn, alder, bostedsfylke og serums lagringstid. Etter dette sto man</p><p align="left">igjen med 114 tilfeller (78 papillære karsinomer, 19 follikulære og 17 av andre histologiske typer) og 333</p><p align="left">kontroller. Albumin i serum ble bestemt med bromkresolgrønt-metoden og fri fettsyrer ble bestemt med en</p><p align="left">enzymatisk metode. Resultatene av denne populasjonsbaserte pasient-kontroll studien ble i korthet at man</p><p align="left">etter justering for fri fettsyrer ikke fant noen sammenheng mellom s-albumin og kreftrisiko for tilfeller der</p><p align="left">serum var tatt mer enn 6,6 år før diagnose. For serum tatt mindre enn 6,6 år før diagnose var det derimot en</p><p align="left">mulig positiv assosiasjon for de papillære karsinomene og en sannsynlig positiv assosiasjon for de follikulære</p><p align="left">karsinomene. Man fant altså ingen invers assosiasjon mellom s-albumin og skjoldkjertelkreft. I en</p><p>kortfattet diskusjon omtales noen konfunderingsfaktorer som kan ha bidratt til resultatet.</p></span></span>

scholarly journals 717. Antibiotic treatment of Shiga toxin-producing Escherichia coli related gastroenteritis and the risk of hemolytic uremic syndrome: a population based matched case-control study in Japan

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S409-S410
Author(s):  
Shota Myojin ◽  
Kyongsun Pak ◽  
Mayumi Sako ◽  
Tohru Kobayashi ◽  
Takuri Takahashi ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Shiga Toxin ◽  
Case Control Study ◽  
Conditional Logistic Regression ◽  
Population Based ◽  
Case Control ◽  
Age Group ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Abstract Background The role of therapeutic intervention, particularly antibiotics, for Shiga toxin-producing Escherichia coli (STEC) related infection is controversial. Methods We performed a population based matched case-control study to assess the association between treatment (antibiotics, antidiarrheal agents and probiotics) for STEC related infections and HUS development. We identified all STEC HUS patients as cases and matched five non-HUS patients as controls using the data from the National Epidemiological Surveillance of Infectious Diseases (NESID) between January 1, 2017, and December 31, 2018. Further medical information was obtained by standardized questionnaires answered by physicians who registered each patient. We used multivariate conditional logistic regression model to evaluate the association between exposures (use of antibiotics, use of antidiarrheal agents, days between disease onset and fosfomycin administration [within two or three days]) and the development of HUS, by matched odds ratios (OR) and 95% confidence intervals (CI). Covariates we used were sex, age group, area code, presence of diarrhea and other factors. We also performed subgroup analyses using age (adults and children) as a stratification factor. Results 7,760 STEC related patients were registered in the NESID. We selected patients who had a record of HUS diagnosis (n=182) and matched controls without HUS (n=910). After collecting standardized paper-based questionnaires, we enrolled 90 HUS patients and 371 non-HUS patients for analysis. In the main analysis, matched OR of fosfomycin was 0.75(0.47-1.20) in all ages, 1.41(0.51-3.88) in adults and 0.58(0.34-1.01) in children. Matched OR of antidiarrheal agents was 2.07(1.07-4.03) in all ages, 1.84(0.32-10.53) in adults, 2.65(1.21-5.82) in children. Matched OR of probiotics was 0.86(0.46-1.61) in all ages, 0.76(0.21-2.71) in adults, 1.00(0.48-2.09) in children. There was no significant association between the timing of fosfomycin use in the first two or five days of illness and HUS development in any age group. Conclusion Our results suggest that fosfomycin might decrease the risk of HUS in children younger than 15 years of age with STEC confirmed bacterial gastroenteritis. Disclosures All Authors: No reported disclosures

scholarly journals Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Susan Shafiei ◽  
Mehrdokht Sadrolodabaei ◽  
Atena Aghaei ◽  
Narjess Ayati ◽  
Samira Zare Namdar ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Response To Treatment ◽  
Control Groups ◽  
Excellent Response ◽  
Significant Difference ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Background: Familial NMTCs are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. Objectives: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of familial and sporadic NMTC. Methods: This is a retrospective study in patients with familial NMTC (at least one other first-degree relative involved) who were treated with surgery, followed by radio-iodine therapy (RIT) without consideration of its familial origin. Response to treatment was compared between familial NMTC and age, sex, and TNM stage-matched non-familial NMTC (control group). Response to treatment was assessed one and two years after RIT, and time to excellent response was identified. Results: Out of 2,944 NMTC patients, 81 (2.75%) patients had familial NMTC. We compared 66 patients with familial NMTC and 66 sporadic NMTC patients. There was no significant difference in first thyroglobulin, initial and accumulative iodine dose, and additional treatments (additional surgery and radiotherapy) between patients and controls. Although no significant difference was noted in one and two years’ responses to treatment between the case and control groups, familial NMTC patients required more time to achieve excellent response (26.7 ± 24.9 versus 15.9 ± 9.0 months, P = 0.01). No significant difference was noted between familial NMTC patients with two or more than two involved relatives. Conclusions: Our study showed that if patients with familial NMTCs were treated in the same way as non-familial patients, the time to excellent response would be significantly longer, even when they have only one other involved relative.

The impact of birthweight on the development of cerebral palsy: A population-based matched case-control study

2021 ◽  
pp. 105533
Author(s):  
Katarina Esih ◽  
Tamara Trunk ◽  
Damjan Osredkar ◽  
Ivan Verdenik ◽  
David Neubauer ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Matched Case ◽  
The Impact ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e043093
Author(s):  
Carlos R Oliveira ◽  
Anette Michelle Ortiz ◽  
Sangini S Sheth ◽  
Eugene D Shapiro ◽  
Linda M Niccolai
Keyword(s):  
Clinical Trials ◽  
Real World ◽  
Hpv Vaccine ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Hpv Vaccines ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

IntroductionIn 2006, the first human papillomavirus (HPV) vaccine was approved by the Food and Drug Administration in the USA based on pre-licensure clinical trials that found it to be highly efficacious at preventing persistent infection and precancerous, high-grade cervical lesions (HGCLs) caused by viral types the vaccine protects against. However, the real-world effectiveness of HPV vaccines as used in clinical practice may be quite different from the efficacy found in pre-licensure clinical trials. More than 10 years have passed since the introduction of the vaccine programme. It is critical to determine if the full benefits of HPV are being realised in real-world settings.Methods and analysisThe objectives of this study were to estimate the effectiveness of HPV vaccines as used in real-world clinical settings and to determine the degree to which the vaccine’s effectiveness varies based on age at the time of immunisation and the number of doses received. The study will be a population-based, matched case–control study. Cases will be women with newly diagnosed HGCL associated with HPV types 16 and 18. Matched controls will be women with a normal Pap test result, matched individually to cases in a 2:1 ratio by age, a practice and date of testing. Medical records will be reviewed to determine dates of receipt of the HPV vaccine for all participants. We will use multivariate conditional logistic regression to control for potential confounders.Ethics and disseminationThis protocol presents minimal risk to the subjects. This protocol has received approval from the Institutional Review Board of Yale University (HIC: 1502015308), and a Health Insurance Portability and Accountability Act (HIPAA) Waiver of Authorisation has been granted to allow investigators to recruit subjects for the study. Findings will be disseminated through peer-reviewed, open-access scientific journals and conference presentations.

Maternal obesity in singleton versus twin gestations: a population-based matched case–control study

2014 ◽  
Vol 28 (6) ◽  
pp. 623-625 ◽  
Author(s):  
Miha Lucovnik ◽  
Isaac Blickstein ◽  
Ivan Verdenik ◽  
Andreja Trojner-Bregar ◽  
Natasa Tul
Keyword(s):  
Maternal Obesity ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document